References
- D’Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol 2006; 7:347 - 58; http://dx.doi.org/10.1038/nrm1910; PMID: 16633337
- Wu JY, Kuo CC. Pivotal role of ADP-ribosylation factor 6 in Toll-like receptor 9-mediated immune signaling. J Biol Chem 2012; 287:4323 - 34; http://dx.doi.org/10.1074/jbc.M111.295113; PMID: 22170068
- Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160:2555 - 9; PMID: 9510150
- Shirota H, Sano K, Hirasawa N, Terui T, Ohuchi K, Hattori T, et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 2001; 167:66 - 74; PMID: 11418633
- Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 2008; 60:795 - 804; http://dx.doi.org/10.1016/j.addr.2007.12.004; PMID: 18262306
- Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471 - 84; http://dx.doi.org/10.1038/nrd2059; PMID: 16763660
- Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117:1184 - 94; http://dx.doi.org/10.1172/JCI31414; PMID: 17476348
- Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 2010; 9:293 - 307; http://dx.doi.org/10.1038/nrd3203; PMID: 20380038
- Häcker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17:6230 - 40; http://dx.doi.org/10.1093/emboj/17.21.6230; PMID: 9799232
- Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190 - 8; http://dx.doi.org/10.1038/ni1028; PMID: 14716310
- Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004; 16:17 - 22; http://dx.doi.org/10.1016/j.smim.2003.10.009; PMID: 14751759
- Guo LH, Schluesener HJ. Binding and uptake of immunostimulatory CpG oligodeoxynucleotides by human neuroblastoma cells. Oligonucleotides 2004; 14:287 - 98; http://dx.doi.org/10.1089/oli.2004.14.287; PMID: 15665596
- Peters PJ, Hsu VW, Ooi CE, Finazzi D, Teal SB, Oorschot V, et al. Overexpression of wild-type and mutant ARF1 and ARF6: distinct perturbations of nonoverlapping membrane compartments. J Cell Biol 1995; 128:1003 - 17; http://dx.doi.org/10.1083/jcb.128.6.1003; PMID: 7896867
- Dascher C, Balch WE. Dominant inhibitory mutants of ARF1 block endoplasmic reticulum to Golgi transport and trigger disassembly of the Golgi apparatus. J Biol Chem 1994; 269:1437 - 48; PMID: 8288610
- Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008; 223:271 - 83; http://dx.doi.org/10.1111/j.1600-065X.2008.00630.x; PMID: 18613842
- Saitoh S, Miyake K. Regulatory molecules required for nucleotide-sensing Toll-like receptors. Immunol Rev 2009; 227:32 - 43; http://dx.doi.org/10.1111/j.1600-065X.2008.00729.x; PMID: 19120473